Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bavarian Nordic (BVNRY : OTC)
 
 • Company Description   
Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.

Number of Employees: 759

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.22 Daily Weekly Monthly
20 Day Moving Average: 6,644 shares
Shares Outstanding: 211.42 (millions)
Market Capitalization: $2,372.12 (millions)
Beta: 1.40
52 Week High: $19.25
52 Week Low: $5.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 52.65% 71.92%
12 Week 17.73% 29.42%
Year To Date -16.58% -1.62%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Philip Heymans Alle 3
-
Hellerup,G7 2900
DNK
ph: 45-3326-8383
fax: 45-3326-8380
investor@bavarian-nordic.com http://www.bavarian-nordic.com
 
 • General Corporate Information   
Officers
Paul Chaplin - Chief Executive Officer and President
Gerard van Odijk - Chairman
Henrik Birk - Chief Operating Office and Executive Vice Presiden
Henrik Juuel - Chief Financial Officer and Executive Vice Preside
Frank Verwiel - Director

Peer Information
Bavarian Nordic (CORR.)
Bavarian Nordic (RSPI)
Bavarian Nordic (CGXP)
Bavarian Nordic (BGEN)
Bavarian Nordic (GTBP)
Bavarian Nordic (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 071771109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/24/22
Share - Related Items
Shares Outstanding: 211.42
Most Recent Split Date: (:1)
Beta: 1.40
Market Capitalization: $2,372.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.07 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/24/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.02
Price/Cash Flow: -
Price / Sales: 8.75
EPS Growth
vs. Year Ago Period: -81.82%
vs. Previous Quarter: -150.00%
Sales Growth
vs. Year Ago Period: -44.37%
vs. Previous Quarter: -42.30%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 2.49
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 2.24
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -23.94
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 5.55
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - 2.31
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.26
09/30/21 - -
 

Powered by Zacks Investment Research ©